“Lower-than-approved doses of GLP-1 medications and isotretinoin (Accutane) are trending on social media. Yale Medicine experts discuss safety, effectiveness, and who may—or may not—be appropriate candidates.
Original story
Continue reading at Yale News - Health & Medicine
news.yale.edu
Summary generated from the RSS feed of Yale News - Health & Medicine. All article rights belong to the original publisher. Click through to read the full piece on news.yale.edu.
